News

AAV patients on rituximab respond poorly to COVID-19 vaccination

Nearly three-quarters of ANCA-associated vasculitis (AAV) patients treated with rituximab fail to mount an effective immune response against SARS-CoV-2, the virus that causes COVID-19, following two doses of vaccines. That’s according to data from the U.K.-based OCTAVE trial, which evaluated immune responses to vaccines in patients with reduced immune…

Central diabetes insipidus more common in AAV patients with GPA

Among people with ANCA-associated vasculitis (AAV), those with central diabetes insipidus are more frequently diagnosed with granulomatosis with polyangiitis (GPA), a type of AAV, according to a study in China. Central diabetes insipidus, or CDI, is a rare disease characterized by excessive thirst and excessive urine. Patients with…

Cyclophosphamide, rituximab may prevent subglottic stenosis relapses

Immunosuppressants may help prevent subglottic stenosis — a condition wherein part of the windpipe becomes tight — from returning in people with a type of ANCA-related vasculitis called granulomatosis with polyangiitis (GPA), a small Italian study suggests. The study, “Role of systemic immunosuppression on subglottic stenosis in granulomatosis…

Blood marker for inflammation may predict AAV disease activity

A blood marker, called C-reactive protein to albumin ratio (CAR), may predict and help monitor disease activity in people with ANCA-associated vasculitis (AAV), according to a small study in Turkey. This is important in clinical practice because “close monitoring, early recognition, and timely treatment of disease activity may limit…

Antibodies against HMGB1 and moesin may be useful biomarkers

Two types of self-reactive antibodies, called anti-HMGB1 and anti-moesin antibodies, are present at significantly higher levels in the blood of ANCA-associated vasculitis (AAV) patients relative to healthy people and those with other autoimmune diseases, a study shows. The levels of these antibodies are also linked to how AAV manifested…